D-二聚體檢測市場 - 全球產業規模、佔有率、趨勢、機會及預測（按產品、測試類型、方法、應用、最終用途、地區和競爭格局分類，2021-2031年）

全球 D-二聚體檢測市場預計將從 2025 年的 20.2 億美元成長到 2031 年的 26.7 億美元，複合年成長率為 4.76%。

這些檢測方法透過定量或定性檢測血液中的纖維蛋白分解物來發揮作用，這些產物是排除肺動脈栓塞、深層靜脈栓塞症和彌散性血管內凝血等血栓事件的重要標記。市場擴張的主要促進因素是全球凝血靜脈血栓栓塞症。此外，急診室也越來越依賴這些檢測方法作為快速排除診斷手段，以簡化患者就診流程並最大限度地減少不必要的住院治療。

然而，該檢測面臨一個重大挑戰：特異性低。與血栓症形成無關的因素（例如惡性腫瘤、發炎、懷孕）會導致假陽性結果，因此需要昂貴的影像檢查才能確診。國際血栓與止血學會（ISSH）在2024年強調了這些疾病的嚴重性，指出血栓症形成佔全球死亡人數的四分之一。雖然這項死亡率凸顯了有效篩檢的必要性，但D-二聚體檢測固有的特異性限制仍然阻礙了其效率，並限制了效用。

市場促進因素

深層靜脈栓塞症(DVT) 和靜脈血栓栓塞症(VTE) 的日益普及是全球 D-二聚體檢測市場的主要促進因素。由於這些疾病的症狀特異性，D-二聚體檢測已成為低危險群至中危險群患者排除血栓栓塞事件的標準初步篩檢方法，有效減少了對昂貴影像檢查的依賴。大量患者需要緊急診斷評估，凸顯了應對此負擔的臨床需求。根據美國疾病管制與預防中心 (CDC) 2024 年 5 月發布的圖表，靜脈血栓栓塞症每年影響約 90 萬美國人。如此高的發病率推動了對自動化平台和高靈敏度試劑的持續需求，以支持快速的臨床決策。

同時，心血管疾病（CVD）發病率的上升顯著推動了對止血檢測的需求。 D-二聚體的應用範圍已從排除性診斷擴展到作為中風、主動脈剝離和心臟衰竭等疾病風險分層的預後標記物，迫使醫療機構加強其診斷能力。美國心臟協會（AHA）於2024年1月報告稱，2021年全球約有1991萬人死於心血管疾病。為順應此趨勢，九龍港務集團宣布其2024年北美銷售額將成長5.2%，證實了心血管風險的增加正直接推動專業診斷技術的商業性發展。

市場挑戰

全球D-二聚體檢測市場面臨的主要限制因素是該檢測本身特異性不足，這常常導致假陽性結果。由於非血栓性生理狀況，例如發炎、惡性腫瘤和妊娠，也會導致D-二聚體水平升高，因此僅憑陽性結果並不能確診血栓症形成。這項限制迫使醫療機構進行昂貴且耗費資源的影像檢查（例如，肺動脈CT血管血管造影術）以排除肺動脈栓塞等疾病。因此，這些輔助檢查帶來的經濟和營運負擔降低了單獨進行D-二聚體檢測的成本效益，使其功能僅限於排除性診斷，而非確診。

這種低效性造成了臨床工作流程中的重大瓶頸，尤其考慮到需要評估的症狀患者數量龐大。根據美國心臟協會2024年報告，美國所有靜脈血栓栓塞症的估計發生率為每10萬人年264.6例。鑑於血栓性疾病的高發生率，D-二聚體檢測無法準確區分真陽性和假陽性，這給醫療保健系統帶來了不必要的成本，並直接抑制了市場潛在的臨床應用擴張。

市場趨勢

新一代就地檢驗設備的普及正在從根本上改變市場格局，將診斷從集中式檢查室轉移到分散式環境。這項轉變的驅動力在於攜帶式多功能檢測平台的廣泛應用，這些平台使臨床醫生能夠在基層醫療醫療機構和患者床邊進行檢查室級的D-二聚體檢測。這種能力對於快速分診和即時治療至關重要，尤其是在基礎設施有限的偏遠地區。羅氏於2024年7月以約2.95億美元收購LumiraDx診斷平台，正是此產業變革的典型例證。此舉凸顯了微流體技術在將關鍵血液凝固檢驗整合到小型裝置方面的商業性價值。

同時，機器學習和人工智慧演算法的融合正在革新D-二聚體檢測的臨床應用，透過先進的預測模型克服其固有的特異性限制。這些演算法結合其他生理指標分析D-二聚體數據，建構穩健的風險分層工具，顯著降低假陽性率，並避免不必要的影像檢查。美國血液學會於2024年12月發布的一份報告特別強調了這種方法的有效性，該報告指出，一種將D-二聚體檢測結果與人工智慧分析的心電圖相結合的新演算法，在預測肺動脈栓塞方面實現了0.93的曲線下面積（AUC）。隨著排除演算法的不斷完善，這些數位化進步正將D-二聚體檢測從簡單的排除性診斷工具提升為精準、自動化臨床決策支援系統的重要組成部分。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球D-二聚體檢測市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品分類（分析設備、試劑和耗材）
  • 依檢測類型（臨床檢測、就地檢驗）
  • 透過以下方法（酵素免疫分析法（ELISA）、乳膠增強免疫比濁法、螢光免疫分析等）
  • 依應用領域（深層靜脈栓塞症、肺動脈栓塞、彌散性血管內凝血等）
  • 依最終用途（醫院、學術/研究機構、診斷中心、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章 北美D-二聚體檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲D-二聚體檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區D-二聚體檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲D-二聚體檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美D-二聚體檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球D-二聚體檢測市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd
• Siemens Healthineers AG
• Abbott Laboratories, Inc.
• bioMerieux SA,
• Werfen, SA
• HORIBA, Ltd.
• QuidelOrtho Corporation
• Diazyme Laboratories, Inc.
• BioMedica Diagnostics Inc.
• Sekisui Diagnostics, LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global D-dimer Testing Market is projected to expand from a valuation of USD 2.02 Billion in 2025 to reach USD 2.67 Billion by 2031, progressing at a CAGR of 4.76%. These tests function by detecting fibrin degradation products quantitatively or qualitatively in the blood, acting as a crucial exclusion marker for thrombotic events like pulmonary embolism, deep vein thrombosis, and disseminated intravascular coagulation. Market expansion is chiefly driven by the rising global incidence of coagulation disorders and a growing elderly population prone to venous thromboembolism. Additionally, emergency departments increasingly rely on these assays for rapid exclusion diagnostics to streamline patient flow and minimize unwarranted hospital admissions.

However, the market confronts a major obstacle regarding the test's low specificity, as factors unrelated to thrombosis-such as malignancy, inflammation, or pregnancy-can trigger false-positive outcomes, necessitating costly confirmatory imaging. The International Society on Thrombosis and Haemostasis highlighted the severity of these conditions in 2024, noting that thrombosis underlies one in four deaths globally. While this mortality rate emphasizes the critical need for effective screening, the inherent specificity limitations of D-dimer assays continue to hinder their efficiency and restrict their standalone utility in clinical settings.

Market Driver

The escalating prevalence of Deep Vein Thrombosis (DVT) and Venous Thromboembolism (VTE) serves as the primary engine for the global D-dimer testing market. Since these conditions manifest with non-specific symptoms, D-dimer assays have become the standard initial screening method to exclude thromboembolic events in low-to-moderate risk patients, effectively reducing reliance on expensive imaging techniques. The clinical necessity to manage this burden is underscored by the high volume of patients requiring urgent diagnostic assessment; according to a May 2024 infographic by the Centers for Disease Control and Prevention, venous thromboembolism impacts nearly 900,000 Americans annually. This high incidence rate drives the continuous demand for automated platforms and high-sensitivity reagents to support rapid clinical decision-making.

Concurrently, the rising rates of cardiovascular diseases (CVD) are significantly increasing the demand for hemostasis testing. D-dimer applications have expanded beyond exclusion to serve as prognostic markers for risk stratification in stroke, aortic dissection, and heart failure cases, prompting healthcare facilities to enhance their diagnostic capabilities. The American Heart Association reported in January 2024 that cardiovascular disease was responsible for roughly 19.91 million deaths globally in 2021. Reflecting this trend, Werfen reported a 5.2% growth in North American sales revenue in 2024, confirming that increasing cardiovascular risks are directly fueling the commercial momentum for specialized diagnostic technologies.

Market Challenge

A major constraint facing the Global D-dimer Testing Market is the assay's inherent lack of specificity, which often leads to false-positive results. Since elevated D-dimer levels can be triggered by non-thrombotic physiological conditions like inflammation, malignancy, or pregnancy, a positive reading cannot definitively diagnose thrombosis. This limitation forces medical providers to employ costly and resource-heavy confirmatory imaging, such as Computed Tomography Pulmonary Angiography, to exclude conditions like pulmonary embolism. Consequently, the financial and operational strain of these secondary procedures diminishes the standalone cost-effectiveness of D-dimer testing, confining it to an exclusionary function rather than a definitive diagnostic role.

This inefficiency generates significant bottlenecks in clinical workflows, particularly considering the high volume of patients presenting with symptoms needing evaluation. As reported by the American Heart Association in 2024, the estimated incidence rate for all venous thromboembolism in the United States was 264.6 per 100,000 person-years. Given such a high incidence of thrombotic conditions, the failure of D-dimer assays to accurately differentiate between actual cases and false alarms imposes avoidable costs on healthcare systems, directly impeding the market's potential for more extensive clinical dependence.

Market Trends

The proliferation of Next-Generation Point-of-Care Testing Devices is fundamentally transforming the market by moving diagnostics from centralized laboratories to decentralized environments. This shift is driven by the broad uptake of portable, multi-assay platforms that enable clinicians to conduct laboratory-grade D-dimer testing in primary care clinics or at the patient's bedside. Such capabilities are essential for speeding up triage and enabling immediate treatment, especially in remote regions with limited infrastructure. This industry-wide transition was validated in July 2024 when Roche acquired LumiraDx's diagnostics platform for roughly $295 million, a move that underscores the commercial value of microfluidic technologies integrating critical coagulation assays into compact devices.

Simultaneously, the integration of Machine Learning and Artificial Intelligence algorithms is revolutionizing the clinical application of D-dimer assays by mitigating their inherent specificity constraints through advanced predictive modeling. These algorithms analyze D-dimer data alongside other physiological metrics to build robust risk stratification tools that notably lower false-positive rates and reduce unnecessary imaging. The effectiveness of this method was highlighted in a December 2024 report by the American Society of Hematology, which noted that a new algorithm combining D-dimer results with AI-analyzed electrocardiograms achieved an area under the curve (AUC) of 0.93 for predicting pulmonary embolisms. By refining exclusion algorithms, these digital advancements are elevating D-dimer tests from simple rule-out tools to integral parts of precise, automated clinical decision support systems.

Key Market Players

• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd
• Siemens Healthineers AG
• Abbott Laboratories, Inc.
• bioMerieux S.A.,
• Werfen, S.A.
• HORIBA, Ltd.
• QuidelOrtho Corporation
• Diazyme Laboratories, Inc.
• BioMedica Diagnostics Inc.
• Sekisui Diagnostics, LLC

Report Scope

In this report, the Global D-dimer Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

D-dimer Testing Market, By Product

• Analyzers
• Reagents & Consumables

D-dimer Testing Market, By Test Type

• Clinical Laboratory Tests
• Point-of-Care Tests

D-dimer Testing Market, By Method

• Enzyme-linked Immunosorbent Assay {ELISA}
• Latex-enhanced Immunoturbidimetric Assays
• Fluorescence Immunoassays
• Others

D-dimer Testing Market, By Application

• Deep Vein Thrombosis
• Pulmonary Embolism
• Disseminated Intravascular Coagulation
• Others

D-dimer Testing Market, By End Use

• Hospitals
• Academic & Research Institutes
• Diagnostic Centers
• Others

D-dimer Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global D-dimer Testing Market.

Available Customizations:

Global D-dimer Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global D-dimer Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Analyzers, Reagents & Consumables)
  • 5.2.2. By Test Type (Clinical Laboratory Tests, Point-of-Care Tests)
  • 5.2.3. By Method (Enzyme-linked Immunosorbent Assay {ELISA}, Latex-enhanced Immunoturbidimetric Assays, Fluorescence Immunoassays, Others)
  • 5.2.4. By Application (Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation, Others)
  • 5.2.5. By End Use (Hospitals, Academic & Research Institutes, Diagnostic Centers, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America D-dimer Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Test Type
  • 6.2.3. By Method
  • 6.2.4. By Application
  • 6.2.5. By End Use
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States D-dimer Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Test Type
      • 6.3.1.2.3. By Method
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By End Use
  • 6.3.2. Canada D-dimer Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Test Type
      • 6.3.2.2.3. By Method
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By End Use
  • 6.3.3. Mexico D-dimer Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Test Type
      • 6.3.3.2.3. By Method
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By End Use

7. Europe D-dimer Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Test Type
  • 7.2.3. By Method
  • 7.2.4. By Application
  • 7.2.5. By End Use
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany D-dimer Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Test Type
      • 7.3.1.2.3. By Method
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By End Use
  • 7.3.2. France D-dimer Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Test Type
      • 7.3.2.2.3. By Method
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By End Use
  • 7.3.3. United Kingdom D-dimer Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Test Type
      • 7.3.3.2.3. By Method
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By End Use
  • 7.3.4. Italy D-dimer Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Test Type
      • 7.3.4.2.3. By Method
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By End Use
  • 7.3.5. Spain D-dimer Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Test Type
      • 7.3.5.2.3. By Method
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By End Use

8. Asia Pacific D-dimer Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Test Type
  • 8.2.3. By Method
  • 8.2.4. By Application
  • 8.2.5. By End Use
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China D-dimer Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Test Type
      • 8.3.1.2.3. By Method
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By End Use
  • 8.3.2. India D-dimer Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Test Type
      • 8.3.2.2.3. By Method
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By End Use
  • 8.3.3. Japan D-dimer Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Test Type
      • 8.3.3.2.3. By Method
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By End Use
  • 8.3.4. South Korea D-dimer Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Test Type
      • 8.3.4.2.3. By Method
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By End Use
  • 8.3.5. Australia D-dimer Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Test Type
      • 8.3.5.2.3. By Method
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By End Use

9. Middle East & Africa D-dimer Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Test Type
  • 9.2.3. By Method
  • 9.2.4. By Application
  • 9.2.5. By End Use
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia D-dimer Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Test Type
      • 9.3.1.2.3. By Method
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By End Use
  • 9.3.2. UAE D-dimer Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Test Type
      • 9.3.2.2.3. By Method
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By End Use
  • 9.3.3. South Africa D-dimer Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Test Type
      • 9.3.3.2.3. By Method
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By End Use

10. South America D-dimer Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Test Type
  • 10.2.3. By Method
  • 10.2.4. By Application
  • 10.2.5. By End Use
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil D-dimer Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Test Type
      • 10.3.1.2.3. By Method
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By End Use
  • 10.3.2. Colombia D-dimer Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Test Type
      • 10.3.2.2.3. By Method
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By End Use
  • 10.3.3. Argentina D-dimer Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Test Type
      • 10.3.3.2.3. By Method
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global D-dimer Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. F. Hoffmann-La Roche Ltd
• 15.3. Siemens Healthineers AG
• 15.4. Abbott Laboratories, Inc.
• 15.5. bioMerieux S.A.,
• 15.6. Werfen, S.A.
• 15.7. HORIBA, Ltd.
• 15.8. QuidelOrtho Corporation
• 15.9. Diazyme Laboratories, Inc.
• 15.10. BioMedica Diagnostics Inc.
• 15.11. Sekisui Diagnostics, LLC

16. Strategic Recommendations

17. About Us & Disclaimer